TrialThe oncologist2024

TRIUMPH: phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline homologous recombination repair gene mutations.

Mark C Markowski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.